Table 2.
Clinical studies of HC-DBS for the treatment of Epilepsy.
| Author/year | Mean age (years) | Type of study | n | Seizure type (s) | Follow up (months) | Average seizure reduction (range) |
|---|---|---|---|---|---|---|
| HC | ||||||
| Velasco et al. (113, 114) | 24 | Open label | 10 | (TLE) CPS, SGTC | 2 weeks | 100% after 6 days |
| Vonck, 2002 (115) | 33 | Open label | 3 | (MTLE) CPS, GTC | 5 (3–6) | 77% (50–94%) |
| Vonck et al. (116) | NR | Open label | 7 | (TLE)NR | 14 (5.5–21) | 43% (0–100%) |
| Tellez-Zenteno et al. (98) | 32 | Clinical trial (Double blind, cross over) | 4 | (MTLE)CPS, SGTC | 6 blind | 26% (ON) vs. −49% (OFF) |
| Boon et al. (105) | NR | Open label | 10 | (MTLE)CPS, SPS, SGTC | 31 (15–52) | 50% (< 30–100%) |
| Velasco et al. (109, 117) | 29 | Clinical trial | 9 | (MTLE)CPS, SGTC | 18 (1 blind) | 83% (50–100%);9/9 RR |
| McLachlan et al. (106) | 45, 54 | Clinical trial(Double blind, cross over) | 2 | NR | 3 | 33% (ON) vs. 4% (OFF) |
| Boex et al. (110)Bondallaz et al. (118) | 34 | Open label | 8 | (MTLE) CPS, SGTC | 44 | 67% (0–100%);6/8 RR |
| Tyrand, 2012 (119) | 32 | Open label | 12 | (TLE)NR | 0 | 58.1%* |
| Morrell et al. (53) (RNS trial)Heck et al. (54) (RNS trial) | 34.9 (18–66) | Clinical trial | 95 of 191 | SPS, CPS, SGTC | 3 blind 48 | 38% (ON) vs. 17% (OFF)53%,55% RR |
| Vonck et al. (107) | NR | Open label | 11 | (MTLE)CPS, SPS, SGTC | 96 (67–120) | 70% (0–100%);8/11 RR; |
| Cukiert et al. (57) | 37 | Single blind | 9 | (TLE) CPS, SPS, SGTC | 30.1 | 61% (−50–100%); 7/9 RR |
| Jin et al. (120) | NR | Open label | 3 | CPS, SGTC | 35 | 93% (91–95%) |
| Lim et al. (121) | 35 | Open label | 5 | CPS, SGTC | 38 | 45% (22–72%); 3/5 RR |
| Cukiert et al. (108) | 38.4 | Clinical trial (Double blind, randomized) | 16 | SPS, CPS | 8 (6 blind) | 3/14 RR in CPS, 7/16 RR in SPS |
Seizure types: P, Partial; CS, Clonic; SPS, Simple partial seizure; CPS, Complex partial seizure; DA, Drop attack: atonic; DIA, Dialeptic; GTC, Generalized tonic-clonic; AA, Atypical absence; SGTC, Secondarily generalized; PM, Partial motor; TS, Tonic; HM, Hypermotor; MYO, Myoclonic; PME, Progressive myoclonic epilepsy.
Targets: ATN, Anterior thalamic nucleus; VIM, Ventral intermediate nucleus of thalamus; STN, Subthalamic nucleus; HC, Hippocampus.
Seizure onset: Bi, Bilateral; Uni, Unilateral; TLE, Temporal lobe epilepsy; MTLE, medial temporal lobe epilepsy; FLE, Frontal lobe epilepsy.
Outcomes: RR: Responders rate (Seizure reduction ≥50%).
Other: NR, Not report.
Outcome: Reduction of interictal activity with biphasic stimulation in Hippocampal sclerosis (119).